47.65

2.78% 1.2487

Moonlake Immunotherapeutics (MLTX)

Overview News Price History Option Chain Financials Why MLTX Down? Discussions Forecast

Moonlake Immunotherapeutics stock is traded at $47.65, with a volume of 111.42K. It is up +2.78% in the last 24 hours and down -13.73% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Previous Close:

$46.40

Open:

$47.22

24h Volume:

111.42K

Relative Volume:

0.37

Market Cap:

$2.93B

Revenue:

Net Income/Loss:

$-54.80M

P/E Ratio:

-40.75

EPS:

-1.1692

Net Cash Flow:

$-64.65M

1W Performance:

-1.04%

1M Performance:

-13.73%

6M Performance:

+5.37%

1Y Performance:

-7.00%

1-Day Range:

$45.91

$47.81

1-Week Range:

$45.24

$48.16

52-Week Range:

$35.11

$64.98

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name

Moonlake Immunotherapeutics

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

41 41 510 8022

Address

DORFSTRASSE 29, ZUG

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

MLTX's Discussions on Twitter

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-08-23	Initiated	Citigroup	Buy
Nov-02-23	Initiated	Stifel	Buy
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy
Jun-15-23	Initiated	Barclays	Equal Weight
May-01-23	Initiated	Guggenheim	Buy
Mar-22-23	Initiated	Wedbush	Outperform
Mar-09-23	Initiated	BTIG Research	Buy
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight
Feb-02-23	Initiated	Bryan Garnier	Buy
Nov-11-22	Initiated	Jefferies	Buy
Aug-25-22	Initiated	SVB Leerink	Outperform
Jul-21-22	Initiated	H.C. Wainwright	Buy
Jul-07-22	Initiated	Cowen	Outperform

View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

08:39 AM

Wedbush Reiterates "Outperform" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

08:39 AM

08:08 AM

14,000 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by AlphaCentric Advisors LLC - MarketBeat

08:08 AM

Nov 04, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat

Nov 04, 2024

Nov 03, 2024

Long Term Trading Analysis for (MLTX) - Stock Traders Daily

Nov 03, 2024

Nov 02, 2024

Congress Asset Management Co. Makes New Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 02, 2024

Oct 30, 2024

MLTX Makes Notable Cross Below Critical Moving Average - Nasdaq

Oct 30, 2024

Oct 29, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.45 Average PT from Brokerages - MarketBeat

Oct 29, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Oct 29, 2024

Oct 26, 2024

MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts - MSN

Oct 26, 2024

Oct 25, 2024

I'm Eyeing 2 Promising Biotech Plays as Oversold Market Gets Under My Skin - TheStreet

Oct 25, 2024

Oct 24, 2024

This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St

Oct 24, 2024

Oct 23, 2024

(MLTX) Proactive Strategies - Stock Traders Daily

Oct 23, 2024

Oct 17, 2024

HC Wainwright Reiterates “Buy” Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Oct 17, 2024

Oct 16, 2024

H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares By Investing.com - Investing.com Nigeria

Oct 16, 2024

H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares - Investing.com India

Oct 16, 2024

Oct 15, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Reiterated by HC Wainwright - MarketBeat

Oct 15, 2024

Oct 13, 2024

MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold (NASDAQ:MLTX) - Seeking Alpha

Oct 13, 2024

Oct 12, 2024

When (MLTX) Moves Investors should Listen - Stock Traders Daily

Oct 12, 2024

Oct 10, 2024